According to GlobalData’s medical device pipeline database, 11 Integrated Clinical Chemistry & Immunochemistry Analyzers devices are in various stages of development globally. GlobalData’s report Integrated Clinical Chemistry & Immunochemistry Analyzers provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, five are in active development, while the remaining six are in an inactive stage of development. There are one products in the early stages of development, and the remaining four are in the late stages of development.
In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. An integrated clinical chemistry and immunochemistry analyzer is a laboratory instrument that can perform both clinical chemistry and immunochemistry tests on a single platform. An Integrated Clinical Chemistry and Immunochemistry analyzer utilizes a single platform for the simultaneous processing of clinical chemistry assays and immunoassays and provides advantages such as faster turnaround time when compared to individual systems. This type of analyzer can be used to test for a wide range of diseases and conditions. Integrated Clinical Chemistry and Immunochemistry analyzers are most often used for the quantitative determination of biomolecules such as hormones, antibodies to infectious diseases, therapeutic drugs and other proteins in human serum and plasma. Integrated analyzers are tracked under the clinical chemistry category. Integrated analyzers include reader, washer, reagent compartment, cuvettes, pipettes, calibrator and others which are tracked under this segment.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Integrated Clinical Chemistry & Immunochemistry Analyzers pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Integrated Clinical Chemistry & Immunochemistry Analyzers devices. Overall, most of these Integrated Clinical Chemistry & Immunochemistry Analyzers pipeline devices are being developed by private entities.
Key players involved in the active development of Integrated Clinical Chemistry & Immunochemistry Analyzers include ADOR Diagnostics, Advanced Liquid Logic, Atonomics, Luminex, Minaris Medical America, MyCartis, NanoIVD, Randox Biosciences, Siemens Healthcare Diagnostics and SynderBio.
For a complete picture of the developmental pipeline for Integrated Clinical Chemistry & Immunochemistry Analyzers devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
